Verrica Pharmaceuticals Inc.
NASDAQ:VRCABiotechnology
-$0.02 today
- Market cap
- $53.94M
- Beta
- 1.49
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$1.67
Volume 0.10M
Average 0.08M
VRCA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Verrica Pharmaceuticals Inc.NASDAQ: VRCA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $9.99M rose 12.9% year over year, ahead of the -29.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 23.1% from the prior quarter. Over 3 fiscal years it compounded at +26.5% a year.
Context
- Selling, general & admin amounted to 99.0% of revenue in FY2025, down 678.5 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $109.23M (+210.1%) for the fiscal year ending Dec 2026, a step up from the -40.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $9.99M+23.1% QoQ
- Last fiscal yearDec 2025
- $35.22M-40.1% YoY
- LTMMar 2026
- $36.36M-29.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 35.22M USD
- Year-over-year change
- -40.1%
- 4-year CAGR
- +6.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.22M | -40.1% |
| FY2024 | 2024-12-31 | 58.82M | +24.3% |
| FY2023 | 2023-12-31 | 47.31M | +171.8% |
| FY2022 | 2022-12-31 | 17.41M | -35.5% |
| FY2021 | 2021-12-31 | 26.98M | — |
Selling, General & Admin vs competitors
How VRCA compares with its peers on the latest reported figures
- VRCA's LTM Mar 2026 selling, general & admin of $36.36M is the highest of the 5 companies compared; the peer median is $17.66M.
- Its year-over-year change of -29.2% is the lowest of 5, against a peer median of -5.5%.
- Selling, general & admin amounts to 97.8% of revenue for VRCA, versus a peer median of 31.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $36.36M | -29.2% | +26.5% | 97.8% | |
| LTM Jun 2026 | $21.82M | +116.7% | -3.8% | — | |
| LTM Mar 2026 | $18.25M | -6.2% | +26.2% | — | |
| LTM Mar 2026 | $17.08M | -4.8% | +20.7% | 31.8% | |
| LTM Mar 2026 | $13.3M | -6.8% | +1.5% | — | |
| Peer median (excluding VRCA) | $17.66M | -5.5% | +11.1% | 31.8% | |
Competitors are the stored peer set for VRCA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12M | 9.03M | 5.12M | 7.57M | 35.58M |
| Cost of Revenue | 472K | 725K | 746K | 2.74M | 3.44M |
| Gross Profit | 11.53M | 8.31M | 4.38M | 4.83M | 32.14M |
| Gross Margin | 96.1% | 92.0% | 85.4% | 63.8% | 90.3% |
| Research & Development | 15.93M | 12.2M | 20.3M | 11.84M | 8.86M |
| Selling, General & Admin | 26.98M | 17.41M | 47.31M | 58.82M | 35.22M |
| Operating Expenses | 42.44M | 29.6M | 70.14M | 70.75M | 44.08M |
| Depreciation & Amortization | 472K | 718K | 836K | 1.27M | 781K |
| EBITDA | (30.31M) | (21.6M) | (62.2M) | (65.9M) | (9.36M) |
| EBITDA Margin | -252.6% | -239.1% | -1213.8% | -871.0% | -26.3% |
| Operating Income | (30.91M) | (21.3M) | (65.76M) | (65.92M) | (11.94M) |
| Operating Margin | -257.6% | -235.8% | -1283.4% | -871.3% | -33.6% |
| Interest Income | 123K | 476K | 2.74M | 1.42M | 929K |
| Interest Expense | 4.3M | 2.17M | 3.96M | 9.41M | 7.74M |
| Other Income / Expenses | (4.17M) | (3.19M) | (1.24M) | (10.66M) | (5.95M) |
| Income Before Tax | (35.08M) | (24.49M) | (67M) | (76.58M) | (17.89M) |
| Pre-Tax Margin | -292.3% | -271.1% | -1307.5% | -1012.1% | -50.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (35.08M) | (24.49M) | (67M) | (76.58M) | (17.89M) |
| Net Margin | -292.3% | -271.1% | -1307.5% | -1012.1% | -50.3% |
| EPS (Basic) | (12.97) | (7.17) | (14.78) | (14.78) | (1.68) |
| EPS (Diluted) | (12.97) | (7.17) | (14.78) | (14.78) | (1.68) |
| Weighted Avg Shares | 2.7M | 3.42M | 4.53M | 5.18M | 10.65M |
| Weighted Avg Shares (Diluted) | 2.7M | 3.42M | 4.53M | 5.18M | 10.65M |
Verrica Pharmaceuticals Inc.
NASDAQ:VRCA
Intrinsic Alpha fair value
Locked
Current Price
$3.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.